nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranexamic Acid—PLG—neck—esophageal cancer	0.0527	0.255	CbGeAlD
Tranexamic Acid—Venous thrombosis—Carboplatin—esophageal cancer	0.0377	0.0865	CcSEcCtD
Tranexamic Acid—PLG—epithelium—esophageal cancer	0.0359	0.173	CbGeAlD
Tranexamic Acid—PLG—smooth muscle tissue—esophageal cancer	0.0346	0.167	CbGeAlD
Tranexamic Acid—PLG—digestive system—esophageal cancer	0.0273	0.132	CbGeAlD
Tranexamic Acid—Cerebral thrombosis—Methotrexate—esophageal cancer	0.0261	0.0599	CcSEcCtD
Tranexamic Acid—PLG—lung—esophageal cancer	0.0228	0.11	CbGeAlD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP14—esophageal cancer	0.0206	0.0576	CbGpPWpGaD
Tranexamic Acid—Diuresis—Cisplatin—esophageal cancer	0.0193	0.0442	CcSEcCtD
Tranexamic Acid—Thromboembolic event—Capecitabine—esophageal cancer	0.0163	0.0375	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—PRDX2—esophageal cancer	0.016	0.0447	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—PRDX1—esophageal cancer	0.016	0.0447	CbGpPWpGaD
Tranexamic Acid—Hemiparesis—Methotrexate—esophageal cancer	0.0156	0.0359	CcSEcCtD
Tranexamic Acid—PLG—amb2 Integrin signaling—HMGB1—esophageal cancer	0.0147	0.0411	CbGpPWpGaD
Tranexamic Acid—Joint stiffness—Capecitabine—esophageal cancer	0.0146	0.0334	CcSEcCtD
Tranexamic Acid—PLG—Orphan transporters—SLC10A2—esophageal cancer	0.014	0.0391	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—PFN1—esophageal cancer	0.0126	0.0354	CbGpPWpGaD
Tranexamic Acid—Thromboembolic event—Methotrexate—esophageal cancer	0.0122	0.0279	CcSEcCtD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—PFN1—esophageal cancer	0.012	0.0337	CbGpPWpGaD
Tranexamic Acid—SLC15A2—bronchus—esophageal cancer	0.0113	0.0546	CbGeAlD
Tranexamic Acid—Venous thrombosis—Cisplatin—esophageal cancer	0.0111	0.0254	CcSEcCtD
Tranexamic Acid—PLG—Platelet degranulation—CFL1—esophageal cancer	0.0102	0.0287	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—XIAP—esophageal cancer	0.0102	0.0285	CbGpPWpGaD
Tranexamic Acid—SLC15A2—trachea—esophageal cancer	0.0101	0.049	CbGeAlD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—CFL1—esophageal cancer	0.00975	0.0273	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP14—esophageal cancer	0.00908	0.0254	CbGpPWpGaD
Tranexamic Acid—Venous thrombosis—Capecitabine—esophageal cancer	0.00815	0.0187	CcSEcCtD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—SOD2—esophageal cancer	0.00789	0.0221	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—HSPA5—esophageal cancer	0.00787	0.022	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—HSPA5—esophageal cancer	0.0075	0.021	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—PTGS1—esophageal cancer	0.00747	0.0209	CbGpPWpGaD
Tranexamic Acid—SLC15A2—lung—esophageal cancer	0.00729	0.0352	CbGeAlD
Tranexamic Acid—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00723	0.0166	CcSEcCtD
Tranexamic Acid—Embolism—Capecitabine—esophageal cancer	0.00686	0.0157	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—SOD2—esophageal cancer	0.00642	0.018	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PFN1—esophageal cancer	0.00561	0.0157	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—CAPZA1—esophageal cancer	0.00559	0.0156	CbGpPWpGaD
Tranexamic Acid—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00547	0.0126	CcSEcCtD
Tranexamic Acid—Deep vein thrombosis—Methotrexate—esophageal cancer	0.00538	0.0124	CcSEcCtD
Tranexamic Acid—Embolism—Methotrexate—esophageal cancer	0.0051	0.0117	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—SOD2—esophageal cancer	0.0051	0.0143	CbGpPWpGaD
Tranexamic Acid—SLC15A2—lymph node—esophageal cancer	0.00499	0.0241	CbGeAlD
Tranexamic Acid—Polyuria—Cisplatin—esophageal cancer	0.00494	0.0113	CcSEcCtD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—NOS3—esophageal cancer	0.00492	0.0138	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.00454	0.0127	CbGpPWpGaD
Tranexamic Acid—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00448	0.0103	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00442	0.0101	CcSEcCtD
Tranexamic Acid—Pulmonary embolism—Capecitabine—esophageal cancer	0.0044	0.0101	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.00428	0.012	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—esophageal cancer	0.00393	0.011	CbGpPWpGaD
Tranexamic Acid—Cramp muscle—Cisplatin—esophageal cancer	0.0039	0.00895	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP14—esophageal cancer	0.0038	0.0107	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—ATP1B2—esophageal cancer	0.0037	0.0104	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—esophageal cancer	0.00367	0.0103	CbGpPWpGaD
Tranexamic Acid—Polyuria—Capecitabine—esophageal cancer	0.00364	0.00835	CcSEcCtD
Tranexamic Acid—Swelling—Capecitabine—esophageal cancer	0.00362	0.00831	CcSEcCtD
Tranexamic Acid—Abdominal discomfort—Cisplatin—esophageal cancer	0.00359	0.00824	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.00349	0.00977	CbGpPWpGaD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00341	0.00955	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00341	0.00954	CbGpPWpGaD
Tranexamic Acid—Atrial fibrillation—Capecitabine—esophageal cancer	0.00337	0.00773	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—DOCK2—esophageal cancer	0.00335	0.00937	CbGpPWpGaD
Tranexamic Acid—Respiratory failure—Methotrexate—esophageal cancer	0.00334	0.00765	CcSEcCtD
Tranexamic Acid—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00329	0.00755	CcSEcCtD
Tranexamic Acid—Renal failure—Cisplatin—esophageal cancer	0.00328	0.00753	CcSEcCtD
Tranexamic Acid—Pulmonary embolism—Methotrexate—esophageal cancer	0.00328	0.00752	CcSEcCtD
Tranexamic Acid—Myocardial infarction—Cisplatin—esophageal cancer	0.00327	0.00751	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00326	0.00748	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.0032	0.00897	CbGpPWpGaD
Tranexamic Acid—Migraine—Capecitabine—esophageal cancer	0.00314	0.00721	CcSEcCtD
Tranexamic Acid—SLC15A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00312	0.00874	CbGpPWpGaD
Tranexamic Acid—PLG—Orphan transporters—CREBBP—esophageal cancer	0.00306	0.00856	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00304	0.0085	CbGpPWpGaD
Tranexamic Acid—Pulmonary oedema—Methotrexate—esophageal cancer	0.00292	0.00669	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.0029	0.00811	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—PFN1—esophageal cancer	0.00289	0.00809	CbGpPWpGaD
Tranexamic Acid—Visual impairment—Cisplatin—esophageal cancer	0.00289	0.00663	CcSEcCtD
Tranexamic Acid—PLG—Selenium Micronutrient Network—PTGS2—esophageal cancer	0.00286	0.00801	CbGpPWpGaD
Tranexamic Acid—Eye disorder—Cisplatin—esophageal cancer	0.0028	0.00643	CcSEcCtD
Tranexamic Acid—Flushing—Cisplatin—esophageal cancer	0.00278	0.00638	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Cisplatin—esophageal cancer	0.00278	0.00638	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00278	0.00778	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00278	0.00778	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—esophageal cancer	0.00277	0.00775	CbGpPWpGaD
Tranexamic Acid—Polyuria—Methotrexate—esophageal cancer	0.00271	0.00621	CcSEcCtD
Tranexamic Acid—Immune system disorder—Cisplatin—esophageal cancer	0.00271	0.00621	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Cisplatin—esophageal cancer	0.0027	0.0062	CcSEcCtD
Tranexamic Acid—Angina pectoris—Capecitabine—esophageal cancer	0.00269	0.00617	CcSEcCtD
Tranexamic Acid—Arrhythmia—Cisplatin—esophageal cancer	0.00268	0.00614	CcSEcCtD
Tranexamic Acid—Abdominal discomfort—Capecitabine—esophageal cancer	0.00265	0.00607	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—XBP1—esophageal cancer	0.00263	0.00737	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—SLC30A7—esophageal cancer	0.00252	0.00707	CbGpPWpGaD
Tranexamic Acid—Visual disturbance—Methotrexate—esophageal cancer	0.00251	0.00576	CcSEcCtD
Tranexamic Acid—Muscle spasms—Cisplatin—esophageal cancer	0.00251	0.00576	CcSEcCtD
Tranexamic Acid—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00246	0.00564	CcSEcCtD
Tranexamic Acid—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00243	0.00557	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00243	0.00557	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Cisplatin—esophageal cancer	0.00242	0.00556	CcSEcCtD
Tranexamic Acid—Renal failure—Capecitabine—esophageal cancer	0.00242	0.00555	CcSEcCtD
Tranexamic Acid—Myocardial infarction—Capecitabine—esophageal cancer	0.00241	0.00554	CcSEcCtD
Tranexamic Acid—Anaemia—Cisplatin—esophageal cancer	0.00241	0.00553	CcSEcCtD
Tranexamic Acid—Malaise—Cisplatin—esophageal cancer	0.00235	0.0054	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—CFL1—esophageal cancer	0.00234	0.00655	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—ST6GAL1—esophageal cancer	0.00227	0.00636	CbGpPWpGaD
Tranexamic Acid—Convulsion—Cisplatin—esophageal cancer	0.00226	0.00519	CcSEcCtD
Tranexamic Acid—Myalgia—Cisplatin—esophageal cancer	0.00222	0.0051	CcSEcCtD
Tranexamic Acid—Haemoglobin—Capecitabine—esophageal cancer	0.00222	0.0051	CcSEcCtD
Tranexamic Acid—Haemorrhage—Capecitabine—esophageal cancer	0.00221	0.00507	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—GNG7—esophageal cancer	0.00221	0.00618	CbGpPWpGaD
Tranexamic Acid—Discomfort—Cisplatin—esophageal cancer	0.0022	0.00504	CcSEcCtD
Tranexamic Acid—PLG—Folate Metabolism—TP53—esophageal cancer	0.00214	0.006	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—PIK3CA—esophageal cancer	0.00214	0.00599	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Cisplatin—esophageal cancer	0.00213	0.00489	CcSEcCtD
Tranexamic Acid—Visual impairment—Capecitabine—esophageal cancer	0.00213	0.00489	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00211	0.00589	CbGpPWpGaD
Tranexamic Acid—Nervous system disorder—Cisplatin—esophageal cancer	0.00209	0.00479	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—GDI2—esophageal cancer	0.00207	0.0058	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—TP53—esophageal cancer	0.00207	0.00579	CbGpPWpGaD
Tranexamic Acid—Eye disorder—Capecitabine—esophageal cancer	0.00207	0.00474	CcSEcCtD
Tranexamic Acid—Flushing—Capecitabine—esophageal cancer	0.00205	0.00471	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Capecitabine—esophageal cancer	0.00205	0.00471	CcSEcCtD
Tranexamic Acid—Angiopathy—Capecitabine—esophageal cancer	0.00201	0.0046	CcSEcCtD
Tranexamic Acid—Immune system disorder—Capecitabine—esophageal cancer	0.002	0.00458	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Capecitabine—esophageal cancer	0.00199	0.00457	CcSEcCtD
Tranexamic Acid—Hypotension—Cisplatin—esophageal cancer	0.00199	0.00457	CcSEcCtD
Tranexamic Acid—Arrhythmia—Capecitabine—esophageal cancer	0.00197	0.00453	CcSEcCtD
Tranexamic Acid—Abdominal discomfort—Methotrexate—esophageal cancer	0.00197	0.00452	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00195	0.00545	CbGpPWpGaD
Tranexamic Acid—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00194	0.00445	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00191	0.00535	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Cisplatin—esophageal cancer	0.0019	0.00436	CcSEcCtD
Tranexamic Acid—Back pain—Capecitabine—esophageal cancer	0.00186	0.00427	CcSEcCtD
Tranexamic Acid—Muscle spasms—Capecitabine—esophageal cancer	0.00185	0.00424	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00184	0.00422	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00183	0.00512	CbGpPWpGaD
Tranexamic Acid—Renal failure—Methotrexate—esophageal cancer	0.0018	0.00413	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—HSPA5—esophageal cancer	0.0018	0.00504	CbGpPWpGaD
Tranexamic Acid—Ill-defined disorder—Capecitabine—esophageal cancer	0.00178	0.0041	CcSEcCtD
Tranexamic Acid—Anaemia—Capecitabine—esophageal cancer	0.00178	0.00408	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Cisplatin—esophageal cancer	0.00176	0.00403	CcSEcCtD
Tranexamic Acid—Malaise—Capecitabine—esophageal cancer	0.00173	0.00398	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00173	0.00485	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—KDR—esophageal cancer	0.0017	0.00476	CbGpPWpGaD
Tranexamic Acid—Loss of consciousness—Capecitabine—esophageal cancer	0.00169	0.00388	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00165	0.00463	CbGpPWpGaD
Tranexamic Acid—Haemoglobin—Methotrexate—esophageal cancer	0.00165	0.00379	CcSEcCtD
Tranexamic Acid—Haemorrhage—Methotrexate—esophageal cancer	0.00165	0.00377	CcSEcCtD
Tranexamic Acid—Arthralgia—Capecitabine—esophageal cancer	0.00164	0.00376	CcSEcCtD
Tranexamic Acid—Chest pain—Capecitabine—esophageal cancer	0.00164	0.00376	CcSEcCtD
Tranexamic Acid—Myalgia—Capecitabine—esophageal cancer	0.00164	0.00376	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—ERBB2—esophageal cancer	0.00164	0.00458	CbGpPWpGaD
Tranexamic Acid—Discomfort—Capecitabine—esophageal cancer	0.00162	0.00371	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00159	0.00444	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00159	0.00444	CbGpPWpGaD
Tranexamic Acid—Visual impairment—Methotrexate—esophageal cancer	0.00159	0.00364	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Cisplatin—esophageal cancer	0.00157	0.0036	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—ACTB—esophageal cancer	0.00157	0.00438	CbGpPWpGaD
Tranexamic Acid—Nervous system disorder—Capecitabine—esophageal cancer	0.00154	0.00353	CcSEcCtD
Tranexamic Acid—Eye disorder—Methotrexate—esophageal cancer	0.00154	0.00353	CcSEcCtD
Tranexamic Acid—Asthenia—Cisplatin—esophageal cancer	0.00153	0.00351	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Methotrexate—esophageal cancer	0.00153	0.0035	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—KMT2D—esophageal cancer	0.0015	0.00419	CbGpPWpGaD
Tranexamic Acid—Angiopathy—Methotrexate—esophageal cancer	0.00149	0.00342	CcSEcCtD
Tranexamic Acid—Immune system disorder—Methotrexate—esophageal cancer	0.00149	0.00341	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Methotrexate—esophageal cancer	0.00148	0.0034	CcSEcCtD
Tranexamic Acid—Hypotension—Capecitabine—esophageal cancer	0.00147	0.00337	CcSEcCtD
Tranexamic Acid—Diarrhoea—Cisplatin—esophageal cancer	0.00146	0.00334	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00143	0.00328	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—HSPA5—esophageal cancer	0.00142	0.00396	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Capecitabine—esophageal cancer	0.0014	0.00321	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—CDKN1A—esophageal cancer	0.0014	0.00392	CbGpPWpGaD
Tranexamic Acid—Back pain—Methotrexate—esophageal cancer	0.00139	0.00318	CcSEcCtD
Tranexamic Acid—Dyspepsia—Capecitabine—esophageal cancer	0.00138	0.00317	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—CALR—esophageal cancer	0.00137	0.00384	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00136	0.00311	CcSEcCtD
Tranexamic Acid—Vomiting—Cisplatin—esophageal cancer	0.00135	0.00311	CcSEcCtD
Tranexamic Acid—Fatigue—Capecitabine—esophageal cancer	0.00135	0.00311	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—GHRL—esophageal cancer	0.00135	0.00377	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ADCYAP1—esophageal cancer	0.00133	0.00374	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—ABL1—esophageal cancer	0.00133	0.00373	CbGpPWpGaD
Tranexamic Acid—Ill-defined disorder—Methotrexate—esophageal cancer	0.00133	0.00305	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—FBXW7—esophageal cancer	0.00133	0.00371	CbGpPWpGaD
Tranexamic Acid—Anaemia—Methotrexate—esophageal cancer	0.00132	0.00304	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Capecitabine—esophageal cancer	0.00129	0.00297	CcSEcCtD
Tranexamic Acid—Malaise—Methotrexate—esophageal cancer	0.00129	0.00296	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00128	0.00295	CcSEcCtD
Tranexamic Acid—Nausea—Cisplatin—esophageal cancer	0.00127	0.0029	CcSEcCtD
Tranexamic Acid—Abdominal pain—Capecitabine—esophageal cancer	0.00124	0.00285	CcSEcCtD
Tranexamic Acid—Convulsion—Methotrexate—esophageal cancer	0.00124	0.00285	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—WWOX—esophageal cancer	0.00122	0.00342	CbGpPWpGaD
Tranexamic Acid—Arthralgia—Methotrexate—esophageal cancer	0.00122	0.0028	CcSEcCtD
Tranexamic Acid—Chest pain—Methotrexate—esophageal cancer	0.00122	0.0028	CcSEcCtD
Tranexamic Acid—Myalgia—Methotrexate—esophageal cancer	0.00122	0.0028	CcSEcCtD
Tranexamic Acid—Discomfort—Methotrexate—esophageal cancer	0.0012	0.00276	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.0012	0.00336	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Methotrexate—esophageal cancer	0.00117	0.00268	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00116	0.00326	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—FKBP1A—esophageal cancer	0.00116	0.00325	CbGpPWpGaD
Tranexamic Acid—Hypersensitivity—Capecitabine—esophageal cancer	0.00116	0.00265	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Methotrexate—esophageal cancer	0.00115	0.00263	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—WIF1—esophageal cancer	0.00113	0.00318	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling by PDGF—EGFR—esophageal cancer	0.00113	0.00318	CbGpPWpGaD
Tranexamic Acid—Asthenia—Capecitabine—esophageal cancer	0.00113	0.00258	CcSEcCtD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00112	0.00313	CbGpPWpGaD
Tranexamic Acid—Hypotension—Methotrexate—esophageal cancer	0.00109	0.00251	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00109	0.00305	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Capecitabine—esophageal cancer	0.00107	0.00246	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00106	0.00244	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—CSNK1A1—esophageal cancer	0.00105	0.00293	CbGpPWpGaD
Tranexamic Acid—Dyspnoea—Methotrexate—esophageal cancer	0.00104	0.00239	CcSEcCtD
Tranexamic Acid—Dizziness—Capecitabine—esophageal cancer	0.00104	0.00238	CcSEcCtD
Tranexamic Acid—Dyspepsia—Methotrexate—esophageal cancer	0.00103	0.00236	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00101	0.00231	CcSEcCtD
Tranexamic Acid—Fatigue—Methotrexate—esophageal cancer	0.00101	0.00231	CcSEcCtD
Tranexamic Acid—Vomiting—Capecitabine—esophageal cancer	0.000998	0.00229	CcSEcCtD
Tranexamic Acid—PLG—Signaling by PDGF—PIK3CA—esophageal cancer	0.000985	0.00276	CbGpPWpGaD
Tranexamic Acid—Headache—Capecitabine—esophageal cancer	0.000984	0.00226	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—PFN1—esophageal cancer	0.00098	0.00274	CbGpPWpGaD
Tranexamic Acid—Feeling abnormal—Methotrexate—esophageal cancer	0.000963	0.00221	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—NOS2—esophageal cancer	0.000961	0.00269	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000956	0.00219	CcSEcCtD
Tranexamic Acid—Nausea—Capecitabine—esophageal cancer	0.000933	0.00214	CcSEcCtD
Tranexamic Acid—Abdominal pain—Methotrexate—esophageal cancer	0.000924	0.00212	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—ELMO1—esophageal cancer	0.00088	0.00246	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—CREBBP—esophageal cancer	0.000862	0.00241	CbGpPWpGaD
Tranexamic Acid—Hypersensitivity—Methotrexate—esophageal cancer	0.000861	0.00198	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—AKAP13—esophageal cancer	0.00086	0.00241	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000843	0.00236	CbGpPWpGaD
Tranexamic Acid—Asthenia—Methotrexate—esophageal cancer	0.000839	0.00192	CcSEcCtD
Tranexamic Acid—Diarrhoea—Methotrexate—esophageal cancer	0.0008	0.00183	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000794	0.00222	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PDE4D—esophageal cancer	0.000787	0.0022	CbGpPWpGaD
Tranexamic Acid—Dizziness—Methotrexate—esophageal cancer	0.000773	0.00177	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—NOS3—esophageal cancer	0.000772	0.00216	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—GNG7—esophageal cancer	0.000748	0.00209	CbGpPWpGaD
Tranexamic Acid—PLG—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000747	0.00209	CbGpPWpGaD
Tranexamic Acid—Vomiting—Methotrexate—esophageal cancer	0.000743	0.0017	CcSEcCtD
Tranexamic Acid—Headache—Methotrexate—esophageal cancer	0.000732	0.00168	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—XIAP—esophageal cancer	0.000701	0.00196	CbGpPWpGaD
Tranexamic Acid—Nausea—Methotrexate—esophageal cancer	0.000694	0.00159	CcSEcCtD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000664	0.00186	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CTNNA1—esophageal cancer	0.000663	0.00186	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CXCL2—esophageal cancer	0.000659	0.00185	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000638	0.00179	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PSME2—esophageal cancer	0.000616	0.00172	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PSME1—esophageal cancer	0.000616	0.00172	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ANXA1—esophageal cancer	0.000613	0.00172	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—SST—esophageal cancer	0.000596	0.00167	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—EP300—esophageal cancer	0.000587	0.00164	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—GHRL—esophageal cancer	0.000581	0.00163	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—NOTCH3—esophageal cancer	0.000581	0.00163	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—FBXW7—esophageal cancer	0.000571	0.0016	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—NOTCH2—esophageal cancer	0.000521	0.00146	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TGFBR2—esophageal cancer	0.000462	0.00129	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—SMAD4—esophageal cancer	0.000438	0.00122	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—PIK3CA—esophageal cancer	0.000435	0.00122	CbGpPWpGaD
Tranexamic Acid—SLC15A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000426	0.00119	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—TP53—esophageal cancer	0.00042	0.00118	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—HIF1A—esophageal cancer	0.000358	0.001	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—KDR—esophageal cancer	0.000342	0.000958	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—NOTCH1—esophageal cancer	0.000322	0.000903	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CREBBP—esophageal cancer	0.000292	0.000819	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—NOS3—esophageal cancer	0.000262	0.000733	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—ERBB2—esophageal cancer	0.000245	0.000686	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CCND1—esophageal cancer	0.000216	0.000606	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—CDKN1A—esophageal cancer	0.000209	0.000586	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—EP300—esophageal cancer	0.000199	0.000558	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MYC—esophageal cancer	0.000174	0.000486	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—EGFR—esophageal cancer	0.00017	0.000475	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—PIK3CA—esophageal cancer	0.000147	0.000412	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TP53—esophageal cancer	0.000143	0.000399	CbGpPWpGaD
